Proper Name Recall as an Early Indicator of Preclinical Alzheimer’s Disease Pathology
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Early detection of Alzheimer’s disease (AD) is crucial; however, standard neuropsychological tests often lack sensitivity. Process scores, such as proper name (PN) recall from Logical Memory (LM), may improve the detection of AD-related biomarker positivity. We examined whether baseline PN recall predicted future cerebrospinal fluid (CSF) amyloid (Aβ42/Aβ40) and tau (pTau 181 ) status, and whether biomarker status predicted PN recall trajectories.
Methods
We analyzed 271 cognitively unimpaired BIOCARD participants (mean age = 57.3, 60.3% female, mean follow-up = 15.5) using logistic regression and mixed-effects models to examine the associations between PN recall and CSF biomarkers.
Results
Higher baseline PN recall predicted lower amyloid positivity (odds ratio [OR] = 0.72, p = 0.015). Amyloid and tau positivity have been linked to a faster decline in PN. Biomarker-positive participants in the biomarker-negative group lacked practice effects.
Conclusions
PN recall predicts future AD biomarker positivity and may enhance early detection of AD-related cognitive decline.
